PMID- 27271776
OWN - NLM
STAT- MEDLINE
DCOM- 20170927
LR  - 20190221
IS  - 1538-7151 (Electronic)
IS  - 0277-1691 (Linking)
VI  - 35
IP  - 4
DP  - 2016 Jul
TI  - Aberrant Expression of Anaplastic Lymphoma Kinase in Ovarian Carcinoma 
      Independent of Gene Rearrangement.
PG  - 337-47
LID - 10.1097/PGP.0000000000000260 [doi]
AB  - Ovarian carcinoma is the leading cause of death from gynecologic malignancies. 
      The oncogenic role of anaplastic lymphoma kinase (ALK) is well characterized in 
      many hematopoietic and solid tumors. ALK expression in ovarian carcinoma has been 
      reported but the exact status of ALK protein and its association with 
      clinicopathologic features requires further investigation. ALK expression was 
      determined by immunohistochemistry in 110 primary ovarian carcinomas, including 
      85 cases of serous carcinoma and 25 cases of mucinous carcinoma. Fluorescence in 
      situ hybridization (FISH) and real-time reverse transcription polymerase chain 
      reaction (RT-PCR) were used for evaluating ALK translocation in ALK-positive 
      ovarian carcinomas. Among 110 ovarian carcinomas, 23 (20.9%) cases were ALK 
      positive by immunohistochemistry. All ALK-positive cases were ovarian high-grade 
      serous carcinoma. ALK expression was detected in 23/85 (27.1%) ovarian serous 
      carcinoma and 0/25 (0%) in ovarian mucinous carcinoma. None of the 23 ALK 
      IHC-positive cases harbored ALK gene translocations by FISH or RT-PCR. ALK 
      protein expression was associated with patient age, tumor stage, and histologic 
      type. Specifically, the probability of ALK protein expression was significantly 
      higher in high-grade serous carcinomas in older patients (above 50 y) with 
      advanced disease (FIGO stage III and IV) compared with the low-grade serous and 
      mucinous carcinomas in younger patients with relatively early disease. In 
      conclusion, aberrant ALK expression is observed in ovarian serous carcinoma but 
      not in mucinous carcinoma, is independent of gene translocation, and might be 
      associated with progression and prognosis.
FAU - Tang, Shaoxian
AU  - Tang S
AD  - Department of Pathology (S.T., F.Y., X.D., Y.L., L.Z., X.Z.), Shanghai Cancer 
      Center Department of Oncology (X.D., X.Z.), Shanghai Medical School, Fudan 
      University, Shanghai, China.
FAU - Yang, Fei
AU  - Yang F
FAU - Du, Xiang
AU  - Du X
FAU - Lu, Yongming
AU  - Lu Y
FAU - Zhang, Ling
AU  - Zhang L
FAU - Zhou, Xiaoyan
AU  - Zhou X
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Int J Gynecol Pathol
JT  - International journal of gynecological pathology : official journal of the 
      International Society of Gynecological Pathologists
JID - 8214845
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Adenocarcinoma, Mucinous/diagnosis/*enzymology/genetics/pathology
MH  - Adult
MH  - Aged
MH  - Anaplastic Lymphoma Kinase
MH  - Carcinoma, Ovarian Epithelial
MH  - Cystadenocarcinoma, Serous/diagnosis/*enzymology/genetics/pathology
MH  - Female
MH  - Gene Rearrangement
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Neoplasms, Glandular and Epithelial/diagnosis/*enzymology/genetics/pathology
MH  - Ovarian Neoplasms/diagnosis/*enzymology/genetics/pathology
MH  - Receptor Protein-Tyrosine Kinases/genetics/*metabolism
MH  - Translocation, Genetic
EDAT- 2016/06/09 06:00
MHDA- 2017/09/28 06:00
CRDT- 2016/06/09 06:00
PHST- 2016/06/09 06:00 [entrez]
PHST- 2016/06/09 06:00 [pubmed]
PHST- 2017/09/28 06:00 [medline]
AID - 00004347-201607000-00008 [pii]
AID - 10.1097/PGP.0000000000000260 [doi]
PST - ppublish
SO  - Int J Gynecol Pathol. 2016 Jul;35(4):337-47. doi: 10.1097/PGP.0000000000000260.